Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients

Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the...

Source: Molecular Cancer - November 30, 2023 Category: Cancer & Oncology Authors: Andrea Sacconi, Paola Muti, Claudio Pulito, Giulia Urbani, Matteo Allegretti, Raul Pellini, Nikolay Mehterov, Uri Ben-David, Sabrina Strano, Paolo Bossi and Giovanni Blandino Tags: Correspondence Source Type: research